Hansa Biopharma (HNSA) Stock Overview
A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
HNSA Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Hansa Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 35.00 |
| 52 Week High | SEK 42.98 |
| 52 Week Low | SEK 23.52 |
| Beta | 1.57 |
| 1 Month Change | 11.18% |
| 3 Month Change | 7.10% |
| 1 Year Change | 33.28% |
| 3 Year Change | -16.07% |
| 5 Year Change | -75.99% |
| Change since IPO | 218.18% |
Recent News & Updates
Recent updates
Narrative Update • Jun 14
HNSA: European Licensing Deal Will Drive Future Upside
Analysts have maintained their SEK price target for Hansa Biopharma, citing consistent fair value assumptions along with only minor adjustments to the discount rate, revenue growth, and future P/E inputs. What's in the News Hansa Biopharma reported positive topline data from the European 20-HMedIdeS-19 Post Authorization Efficacy Study of Idefirix in highly sensitized kidney transplant patients, with 1 year graft failure free survival of 90%, 1 year graft survival of 92%, patient survival of 98%, and mean estimated glomerular filtration rate of 52.4 mL/min/1.73 m².Narrative Update • May 31
HNSA: European Licensing Deal And U.S. Review Timeline Will Drive Future Upside
Analysts have adjusted their price target for Hansa Biopharma slightly higher to reflect updated fair value assumptions of around SEK 76 per share, supported by revised discount rate, revenue growth, profit margin and future P/E inputs in their models. What's in the News SERB Pharmaceuticals agreed to acquire exclusive development and commercialisation rights to Idefirix (imlifidase) across Europe, the UK, Switzerland, Norway, Liechtenstein, Iceland and the MENA region for €115 million, including €110 million upfront and €5 million linked to European Medicines Agency full approval filing acceptance (Key Developments).Analysis Article • May 29
Analysts Just Made A Massive Upgrade To Their Hansa Biopharma AB (publ) (STO:HNSA) Forecasts
Hansa Biopharma AB (publ) ( STO:HNSA ) shareholders will have a reason to smile today, with the analysts making...
Narrative Update • May 17
HNSA: FDA Kidney Transplant Review And Phase 3 Success Will Drive Upside
Analysts have kept their SEK fair value estimate for Hansa Biopharma steady at SEK103. Modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E underpin an unchanged price target and reflect updated thinking on the company’s long term earnings potential.Analysis Article • May 11
Analysts' Revenue Estimates For Hansa Biopharma AB (publ) (STO:HNSA) Are Surging Higher
Hansa Biopharma AB (publ) ( STO:HNSA ) shareholders will have a reason to smile today, with the analysts making...Narrative Update • Apr 30
HNSA: U.S. Kidney Transplant Approval Pathway Will Support Future Upside Potential
Analysts have reduced the Hansa Biopharma price target by SEK 8 to SEK 75. This reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples following recent research commentary.Analysis Article • Apr 25
Analysts Just Made A Major Revision To Their Hansa Biopharma AB (publ) (STO:HNSA) Revenue Forecasts
One thing we could say about the analysts on Hansa Biopharma AB (publ) ( STO:HNSA ) - they aren't optimistic, having...Narrative Update • Apr 16
HNSA: Kidney Transplant FDA Review Will Drive Upside Despite Recent Model Reset
Analysts have reduced their SEK price target on Hansa Biopharma by SEK 8, citing updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent commentary around the revised SEK price target highlights how analysts are recalibrating their models rather than shifting their overall view of Hansa Biopharma as a whole.Narrative Update • Apr 02
HNSA: U.S. Kidney Transplant Approval Pathway Will Drive Potential Upside
Analysts have adjusted their price target on Hansa Biopharma by SEK 8, reflecting updated views on the risk profile and near term commercial opportunity for imlifidase, including its potential positioning in kidney transplantation and autoimmune indications. Analyst Commentary Recent research shows a mix of optimism and caution around Hansa Biopharma, with views shaped by the commercial outlook for imlifidase in kidney transplantation and autoimmune indications, as well as how quickly the company can execute on its plans.Narrative Update • Mar 18
HNSA: U.S. Kidney Transplant Decision Timeline Will Shape Future Upside Potential
Analysts now see Hansa Biopharma's fair value moving from about SEK 90 to roughly SEK 81 per share. This reflects updated views on growth, profitability and a higher future P/E, as recent research points to a slightly lower target alongside continued confidence in the commercial potential of imlifidase and the broader pipeline.Narrative Update • Mar 04
HNSA: Kidney Transplant FDA Review And Takeout Appeal Will Drive Upside
Narrative Update Analysts have adjusted their Hansa Biopharma price targets, including an SEK 8 trim at one firm and a SEK 69 initiation at another. These changes reflect updated views on imlifidase, potential FDA approval timing, and the company’s appeal as a possible acquisition candidate in kidney transplantation.Narrative Update • Feb 18
HNSA: Kidney Transplant BLA Filing And Takeout Appeal Will Drive Upside
Narrative Update Opening Analysts have trimmed their 12 month price target on Hansa Biopharma by SEK 8 to SEK 69. This reflects updated assumptions on long term growth, margins and valuation multiples, while still highlighting the commercial potential of imlifidase across transplants, autoimmune disease and gene therapy.
Narrative Update • Feb 04
HNSA: US Kidney Transplant Approval Timing Will Drive Downside Risk
Analysts have nudged their price target for Hansa Biopharma to SEK 69, reflecting updated assumptions on growth, profitability and valuation multiples, supported by views that imlifidase underpins a more de-risked commercial profile across kidney transplantation, autoimmune disease and gene therapy. Analyst Commentary Recent Street research frames Hansa Biopharma as a company with a clearly defined lead asset and a focused commercial plan across kidney transplantation, autoimmune disease and gene therapy.Narrative Update • Jan 20
HNSA: FDA Kidney Transplant Filing Will Drive De-Risked Upside Potential
Analysts have nudged their price expectations for Hansa Biopharma higher, citing new SEK 69 and SEK 100 targets and arguing that the company’s de-risked commercial profile, lead asset imlifidase in kidney transplantation, and potential appeal as an acquisition candidate support a modestly richer P/E driven fair value of SEK 111 per share. Analyst Commentary Recent Street research has leaned constructive on Hansa Biopharma, with price targets clustered around SEK 69 to SEK 100 and commentary that frames the company as a de-risked commercial story anchored by imlifidase in kidney transplantation.Narrative Update • Jan 06
HNSA: Buy Initiation And FDA Filing Will Shape Upside Potential
Analysts have adjusted their price view on Hansa Biopharma from SEK 143 to SEK 111, citing updated assumptions on discount rates, revenue growth, profit margins and future P/E, along with fresh coverage that includes a new SEK 100 target from Street research. Analyst Commentary Bullish analysts see the recent SEK 100 price target as a constructive marker for where Hansa Biopharma could trade if the company executes in line with their assumptions on revenue, margins and future P/E.Narrative Update • Dec 15
HNSA: Gene Therapy Progress And Equity Raise Will Shape Future Upside Risk Balance
Analysts have trimmed their price target on Hansa Biopharma from SEK 100 to SEK 90, citing a slightly higher discount rate and more conservative margin assumptions, even as they highlight the company’s long term growth potential and reiterate a positive view on the shares. Analyst Commentary While the latest adjustments to the price target reflect a more cautious stance on valuation, analysts still point to a differentiated technology platform and growing body of clinical data as key drivers of long term upside potential.Analysis Article • Nov 16
Hansa Biopharma AB (publ) (STO:HNSA) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Hansa Biopharma AB (publ) ( STO:HNSA ) shares have had a horrible month, losing 26% after a relatively good period...Analysis Article • Oct 02
Hansa Biopharma AB (publ) (STO:HNSA) Stocks Shoot Up 29% But Its P/S Still Looks Reasonable
Despite an already strong run, Hansa Biopharma AB (publ) ( STO:HNSA ) shares have been powering on, with a gain of 29...Narrative Update • Aug 20
Global Organ Transplantation Demand Will Expand Market Opportunity
The notable rise in Hansa Biopharma’s consensus analyst price target to SEK90.00 is primarily driven by a substantial increase in its anticipated future P/E multiple, reflecting higher market growth expectations. What's in the News Hansa Biopharma announced topline results from three DMD patients treated with imlifidase prior to ELEVIDYS gene therapy, showing rapid IgG reduction and enabled gene therapy, but with lower micro-dystrophin expression than other trials; next steps to be discussed with Sarepta.
New Narrative • Apr 02
Idefirix Expansion And Clinical Trials Will Open New Markets
Expanding Idefirix in Europe and securing reimbursements may enhance revenue by increasing market penetration and adoption rates.Analysis Article • Feb 12
Downgrade: Here's How Analysts See Hansa Biopharma AB (publ) (STO:HNSA) Performing In The Near Term
The latest analyst coverage could presage a bad day for Hansa Biopharma AB (publ) ( STO:HNSA ), with the analysts...Analysis Article • Feb 09
Hansa Biopharma AB (publ) (STO:HNSA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
As you might know, Hansa Biopharma AB (publ) ( STO:HNSA ) last week released its latest full-year, and things did not...Analysis Article • Feb 08
It's Down 26% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks
Hansa Biopharma AB (publ) ( STO:HNSA ) shareholders that were waiting for something to happen have been dealt a blow...Analysis Article • Dec 22
Hansa Biopharma AB (publ) (STO:HNSA) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Hansa Biopharma AB (publ) ( STO:HNSA ) shareholders are no doubt pleased to see that the share price has bounced 27% in...Analysis Article • Nov 07
It's Down 30% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks
Hansa Biopharma AB (publ) ( STO:HNSA ) shareholders won't be pleased to see that the share price has had a very rough...Analysis Article • Oct 20
Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Last week, you might have seen that Hansa Biopharma AB (publ) ( STO:HNSA ) released its third-quarter result to the...Analysis Article • Aug 24
Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%
Hansa Biopharma AB (publ) ( STO:HNSA ) shareholders have had their patience rewarded with a 28% share price jump in the...Analysis Article • Jul 23
Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%
Today is shaping up negative for Hansa Biopharma AB (publ) ( STO:HNSA ) shareholders, with the analysts delivering a...Analysis Article • Jul 21
Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's shaping up to be a tough period for Hansa Biopharma AB (publ) ( STO:HNSA ), which a week ago released some...Analysis Article • Jun 21
Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package
Key Insights Hansa Biopharma's Annual General Meeting to take place on 27th of June Salary of kr8.43m is part of CEO...Shareholder Returns
| HNSA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 4.4% | 0.8% | 1.3% |
| 1Y | 33.3% | 28.9% | 11.1% |
Return vs Industry: HNSA exceeded the Swedish Biotechs industry which returned 28.9% over the past year.
Return vs Market: HNSA exceeded the Swedish Market which returned 11.1% over the past year.
Price Volatility
| HNSA volatility | |
|---|---|
| HNSA Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: HNSA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: HNSA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 122 | Renee Aguiar-Lucander | www.hansabiopharma.com |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.
Hansa Biopharma AB (publ) Fundamentals Summary
| HNSA fundamental statistics | |
|---|---|
| Market cap | SEK 3.57b |
| Earnings (TTM) | -SEK 691.58m |
| Revenue (TTM) | SEK 190.49m |
18.7x
P/S Ratio-5.2x
P/E RatioIs HNSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HNSA income statement (TTM) | |
|---|---|
| Revenue | SEK 190.49m |
| Cost of Revenue | SEK 76.83m |
| Gross Profit | SEK 113.66m |
| Other Expenses | SEK 805.24m |
| Earnings | -SEK 691.58m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 22, 2026
| Earnings per share (EPS) | -6.80 |
| Gross Margin | 59.67% |
| Net Profit Margin | -363.06% |
| Debt/Equity Ratio | -411.7% |
How did HNSA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/02 20:45 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hansa Biopharma AB (publ) is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Christian Lee | ABG Sundal Collier Sponsored |
| Madhu Kumar | B. Riley Securities, Inc. |